Successful experience of venetoclax in the treatment of refractory primary plasma cell leukemia
https://doi.org/10.17650/1818-8346-2025-20-1-80-87
Abstract
Plasma cell leukemia is a rare, aggressive disease characterized by clonal proliferation of plasma cells, having many features of both plasma cell neoplasms and acute leukemia. despite significant changes in therapeutic approaches, the prognosis for this disease remains unfavorable. The article describes a case of primary plasma cell leukemia in a 62‑year‑old patient who did not respond to the VCD induction program (bortezomib, cyclophosphamide, dexamethasone). Given the presence of t(11;14), a highly selective Bcl‑2 inhibitor, venetoclax, was included in the therapy regimen (ven‑vd regimen). After 3 cycles of venetoclax‑based induction, a very good partial remission was achieved. Then high‑dose MEL200 chemotherapy, autologous hematopoietic stem cell transplantation and 2 cycles of ven‑vd consolidation were implemented, achieving a complete response. MRD‑ negativity (10–5) was confirmed by flow cytometry on bone marrow aspirate at 2 time points. The remission duration at the time of publication was 24 months. The patient continues to receive maintenance therapy with lenalidomide.
Keywords
About the Authors
I. V. CherkashinaRussian Federation
Irina Vasilevna Cherkashina
125284; 3 2nd Botkinskiy Proezd; Moscow
M. A. Vernyuk
Russian Federation
125284; 3 2nd Botkinskiy Proezd; Moscow
S. V. Semochkin
Russian Federation
125284; 3 2nd Botkinskiy Proezd; 117513; 1 Ostrovityanova St.; Moscow
L. S. Khayrullina
Russian Federation
125284; 3 2nd Botkinskiy Proezd; Moscow
A. M. Chervontseva
Russian Federation
125284; 3 2nd Botkinskiy Proezd; Moscow
T. Yu. Smirnova
Russian Federation
125284; 3 2nd Botkinskiy Proezd; Moscow
Kh. S. Kosumova
Russian Federation
125284; 3 2nd Botkinskiy Proezd; Moscow
A. A. Fedenko
Russian Federation
125284; 3 2nd Botkinskiy Proezd; Moscow
References
1. Malignant tumors in Russia in 2021 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 252 p. (In Russ.).
2. Jurczyszyn A., Radocha J., Davila J. et al. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. Br J Haematol 2018;180(6):831–9. DOI: 10.1111/bjh.15092
3. Fernández de Larrea C., Kyle R., Rosiñol L. et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J 2021;11(12):1–5. DOI: 10.1038/s41408021005870
4. Kyle R.A., Maldonado J.E., Bayrd E.D. Plasma cell leukemia: report on 17 cases. Arch Intern Med 1974;133(5):813–8. DOI: 10.1001/archinte.133.5.813
5. Granell M., Calvo X., GarciaGuiñón A. et al. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica 2017;102(6):1099–104. DOI: 10.3324/haematol.2016.158303
6. Ravi P., Kumar S.K., Roeker L. et al. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer J 2018;8(12):1–7. DOI: 10.1038/s4140801801401
7. Guan J., Ma J., Chen B. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study. Hematology 2023;28(1):2254556. DOI: 10.1080/16078454.2023.2254556
8. Chineke I.G., Wertheim B.C., Roe D. et al. Plasma cell leukemia: a multicenter retrospective study of 150 patients. J Clin Oncol 2023;41(16_suppl):8014. DOI: 10.1200/jco.2023.41.16_suppl.8014
9. Suska A., Vesole D.H., Castillo J.J. et al. Plasma cell leukemia – facts and controversies: more questions than answers? Clin Hematol Int 2020;2(4):133–42. DOI: 10.2991/chi.k.200706.002
10. Gupta D., Moule P., Aggarwal C. et al. Improved outcome of primary plasma cell leukemia in the current era with the use of novel agents and autologous bone marrow transplants – a single centre experience. Indian J Hematol Blood Transfus 2024;40(3):400–6. DOI: 10.1007/s12288023017315
11. Gonsalves W.I., Rajkumar S.V., Go R.S. et al. Trends in survival of patients with primary plasma cell leukemia: a populationbased analysis. Blood 2014;124(6):907–12. DOI: 10.1182/blood201403565051
12. Musto P., Simeon V., Martorelli M.C. et al. Lenalidomide and lowdose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia 2014;28(1):222–5. DOI: 10.1038/leu.2013.241
13. Semochkin S.V. New proteasome inhibitors in the management of multiple myeloma. Onkogematologiya = Oncohematology 2019;14(2):29–40. (In Russ.). DOI: 10.17650/1818834620191422940
14. Van de Donk N.W.C.J., Minnema M.C., van der Holt B. et al. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomidebased therapy (EMN12/HOVON129): final analysis of a nonrandomised, multicentre, phase 2 study. Lancet Oncol 2023;24(10):1119–33. DOI: 10.1016/S14702045(23)004059
15. Kumar S., Vij R., Kaufman J.L. et al. Venetoclax monotherapy for relapsed/refractory multiple myeloma: safety and efficacy results from a phase I study. Blood 2016;128(22):488. DOI: 10.1182/blood.v128.22.488.488
16. Kumar S.K., Harrison S.J., Cavo M. et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, doubleblind, multicentre, phase 3 trial. Lancet Oncol 2020;21(12):1630–42. DOI: 10.1016/S14702045(20)305258
17. Tiedemann R.E., GonzalezPaz N., Kyle R.A. et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008;22(5):1044–52. DOI: 10.1038/leu.2008.4
18. Kupsh A., Arnall J., Voorhees P. A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia. J Oncol Pharm Pract 2020;26(5):1274–8. DOI: 10.1177/1078155219895072
19. Gonsalves W.I., Buadi F.K., Kumar S.K. Combination therapy incorporating Bcl2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t(11;14). Eur J Haematol 2018;100(2):215–7. DOI: 10.1111/ejh.12986
20. Jelinek T., Mihalyova J., Kascak M. et al. Singleagent venetoclax induces MRDnegative response in relapsed primary plasma cell leukemia with t(11;14). Am J Hematol 2019;94(1):E35–7. DOI: 10.1002/ajh.25331
21. Drake M.B., Iacobelli S., van Biezen A. et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica 2010;95(5):804–9. DOI: 10.3324/haematol.2009.013334
22. Dhakal B., Patel S., Girnius S. et al. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era [published correction appears in Leukemia 2021;35(7):2141]. Leukemia 2020;34(12):3338–47. DOI: 10.1038/s4137502008300
23. Mahindra A., Kalaycio M.E., VelaOjeda J. et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia 2012;26(5):1091–7. DOI: 10.1038/leu.2011.312
24. Tuazon S.A., Holmberg L.A., Nadeem O., Richardson P.G. A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer J 2021;11(2). DOI: 10.1038/s41408021004146
25. Gowin K., Skerget S., Keats J.J. et al. Plasma cell leukemia : a review of the molecular classification, diagnosis, and evidencedbased treatment. Leuk Res 2021;111:106687. DOI: 10.1016/j.leukres.2021.106687
26. Jones J.R., Cairns D.A., Menzies T. et al. Maintenance lenalidomide in newly diagnosed transplant eligible and noneligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial. EClinicalMedicine 2023;62:102099. DOI: 10.1016/j.eclinm.2023.102099
27. Gowda L., Shah M., Badar I. et al. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant 2019;54(7):1089–93. DOI: 10.1038/s4140901803921
Review
For citations:
Cherkashina I.V., Vernyuk M.A., Semochkin S.V., Khayrullina L.S., Chervontseva A.M., Smirnova T.Yu., Kosumova Kh.S., Fedenko A.A. Successful experience of venetoclax in the treatment of refractory primary plasma cell leukemia. Oncohematology. 2025;20(1):80-87. (In Russ.) https://doi.org/10.17650/1818-8346-2025-20-1-80-87